Propelling Equitable Access to Medicine

About this episode

The episode discusses barriers to equitable access to medicine and how pharmaceutical companies and ESG investors are addressing these challenges.

Access to medicine is a vital issue at the crossroads of global health issue, corporate responsibility, and ESG investing. Join us as we unpack barriers to equitable access, explore how pharmaceutical companies and ESG-focused investors are addressing these challenges, the emergence of patient reach is as a measure of progress, and how improvements in reporting can align access initiatives with business models to drive both sustainable growth and social impact. Birgit Lundem Jakobsen, ESG Specialist at PGIM, hosts this discussion with Bram Wagner, Investor Engagement Lead for the Access to Medicine Foundation, and Hank Balbirer, CFA, U.S. Investment Grade Senior Credit Research Analyst at PGIM. Recorded on November 5, 2025.

People in this episode

Host: Birgit Lundem Jakobsen

Guests: Bram Wagner, Hank Balbirer

Topics covered

• equitable access to medicine
• global health
• corporate responsibility
• ESG investing
• pharmaceutical companies
• sustainable growth
• social impact

Keywords

• access to medicine
• ESG
• pharmaceuticals
• investing
• corporate responsibility
• sustainable growth
• social impact
• healthcare
• reporting
• patient reach

Mentioned in this episode

Organizations: Access to Medicine Foundation, PGIM

More episodes of Fixed on ESG

• Assessing the Risk of Antimicrobial Resistance · February 3, 2026 · 18 min
• COP30: Key Takeaways from the Amazon Summit · December 23, 2025 · 27 min
• Running a Tight Ship: IMO's Net-Zero Regulations · September 23, 2025 · 16 min
• EU ESG Regulation: Players, Policy, and Purpose · September 9, 2025 · 28 min
• The Insurance Industry in the Climate Conversation · July 30, 2025 · 29 min
• Behind the Seams: Unraveling Fast Fashion's ESG Challenges · June 24, 2025 · 20 min